Clinical Trials Browser

Phase 3 × Interventional × belzutifan × Clear all

Carcinoma, Carcinoma, Renal Cell

NCT07405164 2026-03-31

MK-6482-043

Phase 3 Recruiting

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07489495 2026-03-24

LITESPARK-034

Phase 3 Not yet recruiting

758 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04586231 2026-03-05

MK-6482-011

Phase 3 Active not recruiting

747 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase 3 Active not recruiting

249 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05239728 2025-08-14

MK-6482-022

Phase 3 Active not recruiting

1,800 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 2 FDA

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04736706 2024-11-18

MK-6482-012

Phase 3 Active not recruiting

1,653 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Clinical Trials

LITESPARK-033

MK-6482-043

LITESPARK-034

MK-6482-011

MK-6482-022

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

MK-6482-012